Amneal swings to Q3 2026 net loss of $22 million

• Amneal Pharmaceuticals swung to a third-quarter 2026 net loss attributable to shareholders of $22 million, citing acquisition and integration costs and higher taxes.
• Net revenue rose 10% year over year to $863 million, with growth in Affordable Medicines and Specialty partially offset by AvKARE’s decline.
• Management reported that Kashiv integration was proceeding well and highlighted biosimilars and new launches among growth catalysts heading into 2027.
• Full-year 2026 net revenue guidance increased to $3.15 billion–$3.25 billion from $3.10 billion–$3.20 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030600PRIMZONEFULLFEED9868847) on November 03, 2026, and is solely responsible for the information contained therein.